|
Report No. : |
343697 |
|
Report Date : |
06.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
FUTURE
PHARMACEUTICALS INDUSTRIES SAE |
|
|
|
|
Registered Office : |
Building No. 207, Street No. 28, 5th Settlement, 4th Territory Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Date of Incorporation : |
2008 |
|
|
|
|
Com. Reg. No.: |
23188, Cairo |
|
|
|
|
Legal Form : |
Egyptian Joint
Stock Company |
|
|
|
|
Line of Business : |
Engaged in the
manufacture of pharmaceuticals |
|
|
|
|
No. of Employee : |
320 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Egypt |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company Name : FUTURE PHARMACEUTICALS
INDUSTRIES SAE
Country of Origin : Egypt
Legal Form :
Egyptian Joint Stock Company
Registration Date : 2008
Commercial
Registration Number : 23188,
Cairo
Tax Card Number : 245-163-476
Issued Capital : £E
150,000,000
Paid up Capital : £E
150,000,000
Total Workforce :
320
Activities :
Manufacture and distribution of pharmaceuticals.
Financial Condition : Fair
Payments :
Nothing detrimental uncovered
Operating Trend : Steady
Person Interviewed : Dr Huda Samir, Production Manager
FUTURE
PHARMACEUTICALS INDUSTRIES SAE
Location : Building No. 207, Street No. 28, 5th
Settlement, 4th Territory
Town : Cairo
Country : Egypt
Telephone : (20-2) 26180131
Facsimile : (20-2) 26180131
Mobile : (20-11) 6600449 / 11996333
Email : gleithy@future-eg.com / m.tawfik@future-eg.com
Subject operates from
a large suite of offices and a warehouse that are rented and located in the
Central Business Area of Cairo.
Branch Office
(s)
Location Description
·
1st
Industrial Zone, Plot No. 4G Factory
premises
Badr City
Cairo
Tel: (20-2) 28647580 / 28647581 / 28647582
Fax: (20-2) 28647581 / 28647576
Name Position
·
Dr
Gamal Eddine Nasser Eddine El Leithy Chairman
·
Dr Alaa
Mohamed El Jeyoushi Managing
Director
·
Dr
Joseph Ayat Al Shareef Director
·
Dr Mostafa
Awad Director
·
Dr
Ghada Abdullah Al Shareef Director
·
Dr
Tariq El Attar Marketing
Manager
·
Magdy Tawfik Finance
Manager
·
Nasser
Saleh Nasser IT
Manager
·
Marwa
Sultan Administration
Manager
·
Dr Huda Samir Production
Manager
Date of Establishment : 2008, however
full production began in 2011.
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 23188, Cairo
Tax
Card No. : 245-163-476
Issued Capital : £E 150,000,000
Paid up Capital : £E 150,000,000
·
Dr
Gamal Eddine Nasser Eddine El Leithy
·
Dr Alaa
Mohamed El Jeyoushi
·
Dr
Joseph Ayat Al Shareef
·
Dr
Mostafa Awad
·
Dr
Ghada Abdullah Al Shareef
Activities: Engaged in the manufacture of
pharmaceuticals.
Import
Countries: Europe and
India.
International Suppliers:
·
Hitero India
·
Sinochem India
·
DSM India
Operating Trend: Steady
Subject has a
workforce of approximately 320 employees.
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/13: Year Ending
31/12/14:
Total Sales £E 22,000,000 £E 23,600,000
Local sources consider
subject’s financial condition to be Fair.
The above figures
were provided by Mr Dr Huda Samir,
Production Manager
·
National
Societe General Bank
5 Champillion Street
Cairo
Tel: (20-2) 27707000
Fax: (20-2) 27707799
No complaints
regarding subject’s payments have been reported.
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.29 |
|
|
1 |
Rs.99.31 |
|
Euro |
1 |
Rs.73.39 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.